Melissa C.
- Country
- Belgium
- Department
- Neurology
Research Overview
- A Phase 3 Non-inferiority Study Comparing Subcutaneous versus Intravenous Administration of Frexalimab in Adults with Multiple Sclerosis
- Evaluation of Ocrelizumab Efficacy and Safety in Multiple Sclerosis Patients from a Prior Phase IIIb/IV Trial
- Long-term Safety and Efficacy Evaluation of Ocrelizumab in Multiple Sclerosis Patients from Phase III Studies
Data & Insights
Has run more than one trial at 162 of 337 partner sites.
Specializations
Multiple Sclerosis Research
This investigator specializes in the study of multiple sclerosis with a particular focus on both relapsing and progressive forms of the disease. Their research encompasses innovative therapeutic approaches for managing different MS manifestations.
- Relapsing Multiple Sclerosis (RMS)
- Progressive Multiple Sclerosis (PMS)
- Novel Treatment Evaluation
The investigator's work extends to evaluating long-term treatment outcomes in MS patients.
Therapeutic Innovation
Their research portfolio includes studies of various therapeutic agents for MS treatment, including both established and emerging medications. The investigator evaluates disease-modifying therapies with different mechanisms of action.
- BTK Inhibitors
- Monoclonal Antibodies
- Metabolic Modulators
The research focuses on comparative effectiveness of different treatment approaches.
Clinical Outcomes
The investigator examines disease progression markers and treatment effectiveness through various clinical parameters. Their work includes assessment of walking ability and other functional measures in MS patients.
- Long-term Safety Evaluation
- Disease Progression Assessment
- Treatment Tolerability
Research encompasses comprehensive monitoring of therapeutic outcomes and safety profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.